Pulmonary Arterial Hypertension Market

Pulmonary Arterial Hypertension Market by Drug Classes (Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists, Phosphodiesterase 5, and Soluble Guanylate Cyclase Stimulators), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-711
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 3
  • No. Of Pages: 146
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global pulmonary arterial hypertension market size was valued at USD 6.5 billion in 2019 and is anticipated to expand at a CAGR of 5.5% during the forecast period, 2021–2028. The growth of the market is attributed to the rising geriatric population, robust drug pipeline, increasing prevalence of Pulmonary Arterial Hypertension (PAH), and changing lifestyle.

Pulmonary Arterial Hypertension Market Key Takeaways

Favorable government initiatives for orphan drugs development is anticipate to fuel the growth of pulmonary arterial hypertension market. The patient based drug development initiative focuses on patient care in the U.S. This initiative helped in understanding of disease severity, impact of the disease on patients’ lives, and available options for the treatment such as PAH. This initiative also helped for increase in awareness about rare diseases present in the U.S. among people, which aided people to go through diagnosis and take correct treatment for diseases.

Acceleron Pharma, Inc., in September 2019, got FDA approval for Sotatercept as an orphan drug for PAH treatment. Sotatercept was evaluated in two trials as the PULSAR trial and the SPECTRA exploratory trial. In January 2020, the company encountered its primary and secondary key endpoints in patients with PAH. These type of innovations are projected to fuel the market of pulmonary arterial hypertension.

Changes in lifestyle includes excessive smoking habits, lack of physical activity, consumption of fast food, and excessive consumption of alcohol increases the risk of high blood pressure and hypertension. Increased blood pressure successively increases other diseases such as pulmonary arterial hypertension, stroke, and heart attacks. Moreover, detection of PAH due to its nonspecific and mild symptoms.

Market Trends, Drivers, Restraints, and Opportunities

  • Successful launch of innovative drugs & treatment therapies and increasing presence of PAH disease are expected to fuel the market growth.
  • Encouraging government initiatives, increasing unhealthy lifestyle, and other idiopathic conditions are anticipated to boosts the market expansion over the forecast period.
  • Rapid growth in acceptance of treatment and increasing spending on healthcare are factors responsible for the market growth.
  • Patent expiration of drug molecule, termination of drugs by key players during clinical trials, and unawareness about presence of PAH among patients are anticipated to hamper the market expansion.
  • Awareness about side effects of the drugs and high treatment and diagnosis cost are projected to impede the market growth over the forecast period.

Scope of the Report

The report on the global pulmonary arterial hypertension market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Pulmonary Arterial Hypertension Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Drug Classes (Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists, Phosphodiesterase 5, and Soluble Guanylate Cyclase Stimulators)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Johnson & Johnson Private Limited, Gilead Sciences, Inc., United Therapeutics Corporation, GlaxoSmithKline Plc., Pfizer, Inc., Bayer HealthCare, Novartis International AG, Dong-A ST Co., Ltd., Merck Sharp & Dohme Corp., and Arena Pharmaceuticals


Market Segment Insights

Prostacyclin & prostacyclin analogs segment is projected to hold a key market share
Based on drug classes, the pulmonary arterial hypertension market is segmented into prostacyclin & prostacyclin analogs, endothelin receptor antagonists (ERA), phosphodiesterase 5 (PDE-5), and soluble guanylate cyclase (SGC) stimulators. The prostacyclin & prostacyclin analogs segment is expected to hold a key share of the market during the forecast period due to rise in sales of drug for the treatment of PAH. The increasing use of oral prostacyclin agents includes Orenitram and Uptravi for treating pulmonary arterial hypertension.

On the other hand, the endothelin receptor antagonists (ERA) segment is anticipated to expand at a rapid pace during the forecast period. Opsumit and Tracleer target ETB and ETA receptors, while Volibris/Letairis targets the ETA receptor.

North America is expected to dominate the market
On the basis of regions, the pulmonary arterial hypertension market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to dominate the market during the forecast period. The regional market growth can be attributed to the development of healthcare infrastructure in the U.S. Furthermore, high diagnosis rate, favorable government initiatives, and growing awareness are increasing the demand of treatment for pulmonary arterial hypertension. Additionally, in the U.S. the Orphan Drug Act (ODA) 1983 and the Rare Disease Act 2002 has raised acceptance of novel medication for treating pulmonary arterial hypertension.

In Europe, the European Society of Cardiology and European Medicines Agency (EMA) promotes early diagnosis of pulmonary arterial hypertension. Increasing occurrence of risk factors and related diseases such as HIV rises the risk of pulmonary arterial hypertension. Besides, exposure to pollution, growing geriatric population, and lifestyle changes are estimated to fuel the rising prevalence of PAH in the region.

However, Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to rapid economic development, improving healthcare system, and large population base. Also, increasing burden of diseases such as HIV and diabetes is responsible for PAH development, which is expected to propel the regional market growth.

 Pulmonary Arterial Hypertension Market By Regions

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Pulmonary Arterial Hypertension Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Pulmonary Arterial Hypertension Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Pulmonary Arterial Hypertension Market - Supply Chain
  4.5. Global Pulmonary Arterial Hypertension Market Forecast
     4.5.1. Pulmonary Arterial Hypertension Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Pulmonary Arterial Hypertension Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Pulmonary Arterial Hypertension Market Absolute $ Opportunity
5. Global Pulmonary Arterial Hypertension Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Pulmonary Arterial Hypertension Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Pulmonary Arterial Hypertension Demand Share Forecast, 2019-2026
6. North America Pulmonary Arterial Hypertension Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Pulmonary Arterial Hypertension Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Pulmonary Arterial Hypertension Demand Share Forecast, 2019-2026
7. Latin America Pulmonary Arterial Hypertension Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Pulmonary Arterial Hypertension Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Pulmonary Arterial Hypertension Demand Share Forecast, 2019-2026
8. Europe Pulmonary Arterial Hypertension Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Pulmonary Arterial Hypertension Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Pulmonary Arterial Hypertension Demand Share Forecast, 2019-2026
9. Asia Pacific Pulmonary Arterial Hypertension Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Pulmonary Arterial Hypertension Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Pulmonary Arterial Hypertension Demand Share Forecast, 2019-2026
10. Middle East & Africa Pulmonary Arterial Hypertension Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Pulmonary Arterial Hypertension Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Pulmonary Arterial Hypertension Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Pulmonary Arterial Hypertension Market: Market Share Analysis
  11.2. Pulmonary Arterial Hypertension Distributors and Customers
  11.3. Pulmonary Arterial Hypertension Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Johnson & Johnson Private Limited
     11.4.2. Gilead Sciences, Inc.
     11.4.3. United Therapeutics Corporation
     11.4.4. GlaxoSmithKline Plc.
     11.4.5. Pfizer, Inc.
     11.4.6. Bayer HealthCare
     11.4.7. Novartis International AG
     11.4.8. Dong-A ST Co., Ltd.
     11.4.9. Merck Sharp & Dohme Corp.
     11.4.10. Arena Pharmaceuticals
Segments Covered in the Report
The global pulmonary arterial hypertension market has been segmented on the basis of

Drug Classes
  • Prostacyclin & Prostacyclin Analogs
  • Endothelin Receptor Antagonists (ERA)
  • Phosphodiesterase 5 (PDE-5)
  • Soluble Guanylate Cyclase (SGC) Stimulators
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • Johnson & Johnson Private Limited
  • Gilead Sciences, Inc.
  • United Therapeutics Corporation
  • GlaxoSmithKline Plc.
  • Pfizer, Inc.
  • Bayer HealthCare
  • Novartis International AG
  • Dong-A ST Co., Ltd.
  • Merck Sharp & Dohme Corp.
  • Arena Pharmaceuticals

Key players competing in the pulmonary arterial hypertension market include Johnson & Johnson Private Limited, Gilead Sciences, Inc., United Therapeutics Corporation, GlaxoSmithKline Plc., Pfizer, Inc., Bayer HealthCare, Novartis International AG, Dong-A ST Co., Ltd., Merck Sharp & Dohme Corp., and Arena Pharmaceuticals.

Major market players implement several business strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares. For instance, as of July 2019, Remodulin launched by United Therapeutics Corporation. Remodulin medicine is used for the pulmonary arterial hypertension treatment on adult patients.

 Pulmonary Arterial Hypertension Market By Key Players

Buy Report